drugset / Trial / NCT05278728
Phase IIa Study of Nimotuzumab to Treat Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
Nimotuzumab is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR). Clinical efficacy has been shown in adult with head and neck cancer. The study assessed the safety, and efficacy of the combination of Nimotuzumab administered concomitantly with chemotherapy in patients with advanced colorectal cancer.
Timeline
- Start
- 2009-07
- Primary completion
- 2013-08
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 180 mg/m2 | — |
| Subject | Nimotuzumab | Monoclonal antibody | 200 mg | — |
| Subject | Nimotuzumab | Monoclonal antibody | 400 mg | — |
| Subject | Nimotuzumab | Monoclonal antibody | 600 mg | — |
| Subject | Nimotuzumab | Monoclonal antibody | 800 mg | — |